scPharmaceuticals announced that the company is targeting February 20, 2023 as the date for commercial availability of FUROSCIX, a proprietary formulation of furosemide delivered via an On-Body Infusor for outpatient treatment of congestion due to fluid overload in adult patients with New York Heart Association Class II and Class III chronic heart failure. FUROSCIX is not indicated for emergency situations or in patients with acute pulmonary edema. FUROSCIX Infusor will deliver only an 80-mg dose. Management plans to provide a detailed update on the launch and other developments during its regularly scheduled fourth quarter 2022 earnings conference call and webcast in March.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SCPH:
- scPharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
- scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update
- Analysts Say These 2 Stocks Could Double Your Money — Here’s Why They Could Surge
- scPharmaceuticals appoints Nokes as Chief Financial Officer
- scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer
